A Nomogram for Predicting Cancer-specific Survival in Patients with Osteosarcoma As Secondary Malignancy

Overview

Journal Sci Rep

Specialty Science

Date 2020 Aug 1

PMID 32732990

Citations 11

Authors

Yanqi He

Han Liu

Shuai Wang

Jianjun Zhang

Affiliations

Soon will be listed here.

Abstract

The prognostic factors for survival among patients with secondary osteosarcoma remain unclear. The aim of this study was to develop a practical nomogram for predicting cancer-specific survival (CSS) in patients with osteosarcoma as a secondary malignancy. The surveillance, epidemiology, and end results database was used for the identification of osteosarcoma cases. The total sample comprised 5860 cases of primary osteosarcoma and 268 cases of secondary osteosarcoma during the period from 1973 to 2015. The CSS and overall survival (OS) of primary and secondary osteosarcomas were analyzed. The predictors of CSS for secondary osteosarcoma were identified and integrated to build a nomogram. Validation of the nomogram was performed using concordance index (C-index) and calibration plots. The results indicated that patients with secondary osteosarcoma had poorer CSS and OS than patients with primary osteosarcoma. The nomogram model exhibited high discriminative accuracy in the training cohort (C-index = 0.826), which was confirmed in the internal validation cohort (C-index = 0.791). In addition, the calibration plots confirmed good concordance for prediction of CSS at 3, 5, and 10 years. In conclusion, we developed a practical nomogram that provided individual predictions of CSS for patients with secondary osteosarcoma. This nomogram may help clinicians with prognostic evaluations and with the development of individualized therapies for this aggressive disease.

Citing Articles

Survival analysis and prognostic model establishment of secondary osteosarcoma: a SEER-based study.

Wang J, Fu G, Zhu Z, Ding L, Chen Y, Li H Ann Med Surg (Lond). 2024; 86(5):2507-2517.

PMID: 38694292 PMC: 11060285. DOI: 10.1097/MS9.0000000000001898.

Characteristics and prognostic factors of adult patients with osteosarcoma from the SEER database.

Deng G, Chen P Medicine (Baltimore). 2023; 102(37):e33653.

PMID: 37713904 PMC: 10508457. DOI: 10.1097/MD.0000000000033653.

Risk factors for distant metastasis of chondrosarcoma: A population-based study.

Deng G, Wang H, Tan Z, Chen R Medicine (Baltimore). 2023; 102(37):e35259.

PMID: 37713884 PMC: 10508579. DOI: 10.1097/MD.0000000000035259.

Construction of Osteosarcoma Diagnosis Model by Random Forest and Artificial Neural Network.

Li S, Que Y, Yang R, He P, Xu S, Hu Y J Pers Med. 2023; 13(3).

PMID: 36983630 PMC: 10056981. DOI: 10.3390/jpm13030447.

Multiview Deep Forest for Overall Survival Prediction in Cancer.

Li Q, Du Z, Chen Z, Huang X, Li Q Comput Math Methods Med. 2023; 2023:7931321.

PMID: 36714327 PMC: 9876666. DOI: 10.1155/2023/7931321.

References

Ottaviani G, Jaffe N . The etiology of osteosarcoma. Cancer Treat Res. 2010; 152:15-32. DOI: 10.1007/978-1-4419-0284-9_2. View

Calvert G, Randall R, Jones K, Cannon-Albright L, Lessnick S, Schiffman J . At-risk populations for osteosarcoma: the syndromes and beyond. Sarcoma. 2012; 2012:152382. PMC: 3329649. DOI: 10.1155/2012/152382. View

Fujiwara T, Fujiwara M, Numoto K, Ogura K, Yoshida A, Yonemoto T . Second primary osteosarcomas in patients with retinoblastoma. Jpn J Clin Oncol. 2015; 45(12):1139-45. DOI: 10.1093/jjco/hyv140. View

Liao L, Yan H, Mai J, Liu W, Li H, Guo Z . Radiation-induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma. Chin J Cancer. 2016; 35(1):89. PMC: 5059957. DOI: 10.1186/s40880-016-0153-8. View

Behjati S, Gundem G, Wedge D, Roberts N, Tarpey P, Cooke S . Mutational signatures of ionizing radiation in second malignancies. Nat Commun. 2016; 7:12605. PMC: 5027243. DOI: 10.1038/ncomms12605. View

Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo J . Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int. 2016; 2016:3631764. PMC: 4913005. DOI: 10.1155/2016/3631764. View

Kubo T, Furuta T, Johan M, Adachi N, Ochi M . Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis. Skeletal Radiol. 2016; 45(9):1235-42. DOI: 10.1007/s00256-016-2410-y. View

Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P . Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006; 106(5):1154-61. DOI: 10.1002/cncr.21724. View

Barker J, Monument M, Jones K, Putnam A, Randall R . Secondary osteosarcoma: is there a predilection for the chondroblastic subtype?. Orthopedics. 2015; 38(5):e359-66. DOI: 10.3928/01477447-20150504-51. View

10.

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

11.

Young K, Efiong E, Dove J, Blansfield J, Hunsinger M, Wild J . External Validation of a Survival Nomogram for Non-Small Cell Lung Cancer Using the National Cancer Database. Ann Surg Oncol. 2017; 24(6):1459-1464. DOI: 10.1245/s10434-017-5795-5. View

12.

Zheng Z, Lu J, Wang W, Desiderio J, Li P, Xie J . Development and External Validation of a Simplified Nomogram Predicting Individual Survival After R0 Resection for Gastric Cancer: An International, Multicenter Study. Ann Surg Oncol. 2018; 25(8):2383-2390. DOI: 10.1245/s10434-018-6551-1. View

13.

Alba A, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux P . Discrimination and Calibration of Clinical Prediction Models: Users' Guides to the Medical Literature. JAMA. 2017; 318(14):1377-1384. DOI: 10.1001/jama.2017.12126. View

14.

Ottaviani G, Jaffe N . The epidemiology of osteosarcoma. Cancer Treat Res. 2010; 152:3-13. DOI: 10.1007/978-1-4419-0284-9_1. View

15.

Joo M, Kang Y, Ogura K, Iwata S, Kim J, Jeong W . Post-radiation sarcoma: A study by the Eastern Asian Musculoskeletal Oncology Group. PLoS One. 2018; 13(10):e0204927. PMC: 6192585. DOI: 10.1371/journal.pone.0204927. View

16.

Duchman K, Gao Y, Miller B . Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database. Cancer Epidemiol. 2015; 39(4):593-9. DOI: 10.1016/j.canep.2015.05.001. View

17.

Mirabello L, Troisi R, Savage S . Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(7):1531-43. PMC: 2813207. DOI: 10.1002/cncr.24121. View

18.

Sun H, Chen X, Cui J, Zhou Z, Guo K . Prognostic factors to survival of patients with chondroblastic osteosarcoma. Medicine (Baltimore). 2018; 97(39):e12636. PMC: 6181520. DOI: 10.1097/MD.0000000000012636. View

19.

Shaheen M, Deheshi B, Riad S, Werier J, Holt G, Ferguson P . Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma. Clin Orthop Relat Res. 2006; 450:76-81. DOI: 10.1097/01.blo.0000229315.58878.c1. View

20.

Yonemoto T, Hosono A, Iwata S, Kamoda H, Hagiwara Y, Fujiwara T . The prognosis of osteosarcoma occurring as second malignancy of childhood cancers may be favorable: experience of two cancer centers in Japan. Int J Clin Oncol. 2014; 20(3):613-6. DOI: 10.1007/s10147-014-0729-8. View